Skip to main content
. Author manuscript; available in PMC: 2019 Jun 15.
Published in final edited form as: Thromb Haemost. 2015 Jun 11;114(4):735–747. doi: 10.1160/TH14-11-0907

Figure 1. In vitro effect of treprostinil in ECFC viability, clonogenic properties and commitment.

Figure 1.

Figure 1.

A- Proliferation of ECFC cultured in EGM-2/20% FBS, EGM-2/5% FBS and EBM- 2/1% FBS in the presence or in the absence of treprostinil, evaluated after 3 days by measuring cellular phosphatase activity.

B- Effect of treprostinil on ECFC proliferation in EGM-2/5% FBS in the presence or in the absence of Indomethacin evaluated after 3 days by measuring cellular phosphatase activity.

C- Effect of treprostinil on ECFCs proliferation in EGM-2/5% FBS in the presence or in the absence of a cox1 inhibitor SC-560 evaluated after 3 days by measuring cellular phosphatase activity.

D- The percentage of ECFC undergoing at least 1 cell division after 14 days of culture in the presence or in the absence of treprostinil. Results represent the mean ± SEM of 3 independent experiments using single endothelial cells derived from different donors.

E- Number of cell progeny derived from a single ECFC in an individual well after 14 days of culture. Results represent the mean ± SEM of 3 independent experiments.

F- Number of ECFC isolated from umbilical cord blood (CB). Results represent the mean ± SEM ECFC of 5 independent experiments for cord blood samples.